Display options
Cite
Can PK, Degi Rmentepe EN, Etikan P, et al. Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. World Allergy Organ J. 2021;14(7):100554doi: 10.1016/j.waojou.2021.100554.
Can, P. K., Degi Rmentepe, E. N., Etikan, P., Kiziltaç, K., Gelincik, A., Demir, S., Buyukozturk, S., Haşal, E., Bülbül Başkan, E., Aydin, �. �., Maurer, M., Weller, K., & Kocaturk, E. (2021). Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. The World Allergy Organization journal, 14(7), 100554. https://doi.org/10.1016/j.waojou.2021.100554
Can, Pelin Kuteyla, et al. "Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema." The World Allergy Organization journal vol. 14,7 (2021): 100554. doi: https://doi.org/10.1016/j.waojou.2021.100554
Can PK, Degi Rmentepe EN, Etikan P, Kiziltaç K, Gelincik A, Demir S, Buyukozturk S, Haşal E, Bülbül Başkan E, Aydin Ö, Maurer M, Weller K, Kocaturk E. Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. World Allergy Organ J. 2021 Jun 16;14(7):100554. doi: 10.1016/j.waojou.2021.100554. eCollection 2021 Jul. PMID: 34221217; PMCID: PMC8219995.
Copy Download .nbib Format: NLM
Share it on

World Allergy Organ J. 2021 Jun 16;14(7):100554. doi: 10.1016/j.waojou.2021.100554. eCollection 2021 Jul.

Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema.

The World Allergy Organization journal

Pelin Kuteyla Can, Ece Nur Degi Rmentepe, Piril Etikan, Kübra Kiziltaç, Asli Gelincik, Semra Demir, Suna Buyukozturk, Eda Haşal, Emel Bülbül Başkan, Ömür Aydin, Marcus Maurer, Karsten Weller, Emek Kocaturk

Affiliations

  1. Bahcesehir University, Faculty of Medicine, Department of Dermatology, Istanbul, Turkey.
  2. Okmeydani Training and Research Hospital, Dermatology and Venerology, Istanbul, Turkey.
  3. Istanbul University, Istanbul Faculty of Medicine, Adult Allergy Clinic, Istanbul, Turkey.
  4. Uluda? University Faculty of Medicine Department of Dermatology, Bursa, Turkey.
  5. Ankara University Faculty of Medicine, Adult Allergy Clinic, Ankara, Turkey.
  6. Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  7. Koç University School of Medicine Department of Dermatology, Istanbul, Turkey.

PMID: 34221217 PMCID: PMC8219995 DOI: 10.1016/j.waojou.2021.100554

Abstract

OBJECTIVE: Recurrent Angioedema (RAE) is characterized by sudden swelling of mucosal surfaces or deep dermis and is either mast cell-(MMAE) or bradykinin-mediated (BMAE). How patients with BMAE and MMAE differ in terms of disease activity and impact remains largely unknown. Here, we determined validity, reliability, and sensitivity to change of Turkish versions of angioedema activity score (AAS) and quality of life questionnaire (AE-QoL) and used both instruments to investigate and compare patients with BMAE and MMAE.

METHODS: Turkish versions of AAS28 and AE-QoL were applied to 94 patients with RAE (18-72 years). Patients' global self-assessment of QoL (PGA-QoL), disease activity (PGA-DA-VRS, PatGA-DA-VAS), and 12-Item-Short Form Survey were used at week 4 (visit 2), and week 8 (visit 3). Demographic characteristics, clinical features, and AAS28 and AE-QoL values were compared between 31 patients with BMAE and 63 patients with MMAE.

RESULTS: Turkish AAS28 and AE-QoL showed excellent internal consistency, high reproducibility and known-groups validity. Compared to patients with MMAE, BMAE patients were younger (34.6 ± 10.7 vs. 40.7 ± 13.3 years), had longer disease duration (236 ± 178 vs. 51 ± 78 months), high prevalence of family history (63% vs 14%), longer duration of attacks (65 ± 20 vs. 40 ± 25 h), and they were more commonly affected by upper airway angioedema (70% vs 23%). Disease activity (AAS28) was lower (29.3 ± 24.6 vs 55.2 ± 52.9), but AE-QoL was higher (44.2 ± 16.1 vs 34.5 ± 22.5) in BMAE patients as compared to MMAE patients.

CONCLUSIONS: Patients with BMAE and MMAE have distinct disease characteristics. Recurrent bradykinin-mediated angioedema impacts quality of life more than mast cell-mediated angioedema. The discriminating characteristics of patients with BMAE and MMAE may help to improve the diagnosis and management of patients with RAE.

© 2021 The Authors.

Keywords: Angioedema; Angioedema activity score; Angioedema quality of life questionnaire; Bradykinin mediated angioedema; Mast cell mediated angioedema

Conflict of interest statement

Emek Kocaturk reports advisory board fees from 10.13039/100004336Novartis, and has served as a medical advisor for 10.13039/100004326Bayer, Menarini and 10.13039/100004339Sanofi. Marcus Maurer is or r

References

  1. J Investig Allergol Clin Immunol. 2016;26(4):212-21; quiz two pages after page 221 - PubMed
  2. Indian J Anaesth. 2016 Aug;60(8):534-41 - PubMed
  3. World Allergy Organ J. 2011 Feb;4(2 Suppl):S9-S21 - PubMed
  4. Immunol Allergy Clin North Am. 2017 Aug;37(3):467-481 - PubMed
  5. Allergy Asthma Proc. 2017 Nov 30;38(6):447-455 - PubMed
  6. Int J Emerg Med. 2012 Nov 06;5(1):39 - PubMed
  7. World Allergy Organ J. 2008 Jun;1(6):103-13 - PubMed
  8. Clin Chem Lab Med. 2016 Feb;54(2):207-14 - PubMed
  9. Allergy. 2016 Aug;71(8):1203-9 - PubMed
  10. J Allergy Clin Immunol. 2017 Dec;140(6):1710-1713.e11 - PubMed
  11. J Clin Epidemiol. 1998 Nov;51(11):1171-8 - PubMed
  12. Health Qual Life Outcomes. 2012 Jul 20;10:82 - PubMed
  13. Int Immunopharmacol. 2020 Jan;78:106081 - PubMed
  14. J Allergy Clin Immunol Pract. 2020 Jun;8(6):2050-2057.e4 - PubMed
  15. Allergy Asthma Proc. 2015 May-Jun;36(3):213-7 - PubMed
  16. Allergy. 2012 Oct;67(10):1289-98 - PubMed
  17. J Allergy Clin Immunol. 2014 May;133(5):1365-72, 1372.e1-6 - PubMed
  18. Intern Med. 2018 Feb 1;57(3):319-324 - PubMed
  19. Pol Arch Med Wewn. 2016;126(1-2):76-85 - PubMed
  20. J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):246-252 - PubMed
  21. Allergy. 2016 Aug;71(8):1210-8 - PubMed
  22. Allergy. 2014 May;69(5):602-16 - PubMed
  23. Clin Exp Dermatol. 2013 Dec;38(8):870-3 - PubMed
  24. Allergy. 2018 Mar;73(3):576-584 - PubMed
  25. Allergy. 2020 May;75(5):1165-1177 - PubMed
  26. Dermatology. 2019;235(3):167-174 - PubMed
  27. Allergy. 2020 Jan;75(1):224-226 - PubMed
  28. Exp Ther Med. 2019 Feb;17(2):1068-1072 - PubMed
  29. Allergy. 2020 Aug;75(8):2115-2123 - PubMed
  30. Allergy. 2013 Sep;68(9):1185-92 - PubMed
  31. Biomed Res Int. 2019 Oct 31;2019:9157895 - PubMed
  32. Allergy. 2018 Aug;73(8):1724-1734 - PubMed
  33. Clin Transl Allergy. 2015 Feb 04;5(1):5 - PubMed
  34. Front Med (Lausanne). 2017 Dec 04;4:212 - PubMed
  35. World Allergy Organ J. 2019 Jan 26;12(1):100009 - PubMed
  36. Health Qual Life Outcomes. 2019 Oct 26;17(1):160 - PubMed
  37. J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 3:38-44 - PubMed
  38. Acad Emerg Med. 2014 Apr;21(4):469-84 - PubMed
  39. J Investig Allergol Clin Immunol. 2016;26(6):383-386 - PubMed

Publication Types